Tolerability of Remoxipride in the Long Term Treatment of Schizophrenia

  title={Tolerability of Remoxipride in the Long Term Treatment of Schizophrenia},
  author={A. C. Holm and I Edsman and Tommie Lundberg and B. G. Odlind},
  journal={Drug Safety},
Summary506 patients with schizophrenia, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria, were included in a long term treatment programme with remoxipride, a selective dopamine (D2)-receptor antagonist. This overview includes pooled data from all patients who have been treated long term with remoxipride in clinical trials, focusing on patients treated for more than 6 months (n = 283).Remoxipride was administered in daily doses of 75 to 600mg. The… 
5 Citations

Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.

In animals, remoxipride has minimal cataleptic effects at doses that block dopamine agonist-induced hyperactivity and these findings are predictive of antipsychotic activity with a low likelihood of extrapyramidal symptoms.

Phencyclidine in the Social Interaction Test: An Animal Model of Schizophrenia with Face and Predictive Validity

  • F. Sams-Dodd
  • Psychology, Medicine
    Reviews in the neurosciences
  • 1999
PCP effects in the rat social interaction test may be a model of the positive and negative symptoms of schizophrenia with face and predictive validity and that it may be useful for the evaluation of novel antipsychotic compounds.

Weight gain associated with neuroleptic medication: a review.

The empirical literature on weight gain associated with neuroleptic drug use is reviewed, finding that Clozapine and low-potency phenothiazines are associated with the largest gains and molindone with weight loss, but the mechanism is not known.

Comparative evaluation of hERG potassium channel blockade by antipsychotics.

  • J. SilvestreJ. Prous
  • Medicine, Biology
    Methods and findings in experimental and clinical pharmacology
  • 2007
Blockade of human ether-a-go-go-related gene (hERG) potassium channels is an undesirable activity of many drugs because it may be the primary cause for the prolongation of the QT interval, which

Sleep Disturbances as Side Effects of Therapeutic Drugs

Sleep disturbances, as well as other CNS side effects, can be caused by a large variety of therapeutic drugs used for the treatment of a wide range of neurological, psychiatric and medical



Clinical profile of remoxipride ‐ a combined analysis of a comparative double‐blind multicentre trial programme

Remoxipride seems to have a clinical profile characterized by antipsychotic efficacy in acute schizophrenia, apparently equal to that of haloperidol, and good tolerability in being non‐sedative and with low incidences of extrapyramidal, autonomic, and endocrine symptoms.

A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia

There was no statistically significant between‐drug difference in improvement in mental state, as measured by the Brief Psychiatric Rating Scale, although the trend favoured thIORidazine; global assessment of illness severity at the last rating also, favoured thioridazine.

Treatment programme and long‐term outcome in chronic schizophrenia

  • J. Kane
  • Medicine, Psychology
    Acta psychiatrica Scandinavica. Supplementum
  • 1990
Research in recent years has attempted to identify strategies to minimize the risks associated with long‐term treatment (particularly tardive dyskinesia), and other factors influencing long-term outcome have been better studied in combination with controlled drug treatment.

Safety evaluation in both short‐ and long‐term treatment of schizophrenia with remoxipride

Overall, remoxipride appears to offer a high degree of safety in both short‐term and long‐term treatment of schizophrenia, based on the information available at present.

Experiences of long‐term treatment with remoxipride: efficacy and tolerability

Remoxipride can be used safely and with maintained efficacy for long‐term treatment and had a clear cut advantage concerning extrapyramidal symptoms and anticholinergic drugs were needed less frequently with remxipride than with haloperidol.

Distribution of remoxipride to the human brain and central D2‐ dopamine receptor binding examined in vivo by PET

  • L. FardeC. Bahr
  • Psychology, Medicine
    Acta psychiatrica Scandinavica. Supplementum
  • 1990
Positron emission tomography and the ligand [C] raclopride were used to examine the central D2‐dopamine receptor occupancy in man during oral administration of remoxipride and found occupancy values were similar to the values previously found in a series of patients treated with neuroleptics representative of all currently used chemical classes.

Hallucinations in schizophrenia

The prevalence of different types of hallucinations and their clinical correlates were examined in 117 DSM‐III‐R schizophrenic or schizoaffective disorder patients. Auditory hallucinations were by

Neuropharmacological and behavioural properties of remoxipride in the rat

The results suggest that remoxipride, unlike haloperidol, can discriminate between different types of dopamine mediated functions probably by having a preferential action on subpopulations of functionally coupled dopamine D2 receptors.

The prevalence of schizophrenia in three counties in Ireland

A study of the prevalence of schizophrenia in 3 counties in Ireland based on case‐register data and using a standardized diagnostic instrument – the Present State Examination indicates substantial differences between the results of case ascertainment by hospital admission data compared with those arrived at by standardized interview diagnostic techniques.